Aesica Pharmaceuticals - your custom synthesis partner
Aesica is an innovative and service driven supplier of APIs, formulated products and custom synthesis solutions to the global pharmaceutical and biotechnology industries. We have the facilities and expertise to develop products from the early-phase clinical stage right through to commercial supply. We provide a tailored service incorporating integrated project management and working in partnerships on all projects, from individual development and scale-up to large-scale commercial manufacturing and technical transfers.
Custom Synthesis
Our state-of-the-art development facilities comprise fully equipped process development labs, cGMP scale-up facilities and pilot plant.
APIs
We have years of experience in supplying bulk APIs and have built a reputation for reliability, quality and unparalleled service. Our API manufacturing facilities have extensive chemical processing capabilities including potency facilities.
Formulations
We offer an extensive range of process technologies for manufacturing and packaging of formulated products including solid, semi-solid and liquid dosage forms, anaesthetics and potent drugs.
Aesica is granted a licence for manufacturing controlled substances
Aesica Pharmaceuticals, an innovative and service-driven supplier of APIs, finished dosage forms and custom synthesis solutions, announce its licence approval for manufacturing controlled substances.
Aesica's Cramlington, UK site has been recently granted a Home Office licence to allow manufacture and supply of substances listed in Schedule 2 of the Misuse of Drugs Act 1971. Granting of this licence followed a programme of investment carried out to enhance the security of the site and its buildings, and the implementation of special procedures for handling of controlled substances.
These changes allow the Aesica Cramlington site to offer facilities for contract manufacture of controlled active pharmaceutical ingredients in quantities from a few kilogrammes in its GMP pilot plant to tonnes in one of its bulk API plants. The first contract-manufactured controlled drug for one of Aesica's customers is already in production.
Aesica can now offer such controlled drug manufacturing capability at two sites in the UK: Queenborough and Cramlington covering both active ingredient synthesis and manufacture and packaging of finished dosage pharmaceutical forms.
Mr. Adam Sims, Commercial Director of Aesica, said: This is a significant step forward for Aesica in terms of broadening our capabilities in line with our customers" demand..